drugset / Trial / NCT03542838

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

NCT03542838

Phase 1 Completed 94 enrolled Sorrento Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the safety of resiniferatoxin in patients with moderate to severe knee pain due to osteoarthritis.

Timeline

Start
2018-07-12
Primary completion
2020-04-13
Completion
2021-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiniferatoxin Other / unclassified 5 ug Other
Subject Resiniferatoxin Other / unclassified 12.5 ug Other
Subject Resiniferatoxin Other / unclassified 20 ug Other
Subject Resiniferatoxin Other / unclassified 25 ug Other
Subject Resiniferatoxin Other / unclassified 30 ug Other

Indications